Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trudeau’s fine increased

This article was originally published in The Tan Sheet

Executive Summary

The U.S. District Court for the Northern District of Illinois orders infomercial marketer Kevin Trudeau to pay $37 million for violating a 2004 ban from producing or publishing infomercials by misrepresenting the contents of his book "The Weight Loss Cure 'They' Don't Want You to Know About." A judge raised the fine from more than $5 million to the amount consumers paid in response to Trudeau's deceptive infomercials, the Federal Trade Commission announces Jan. 15. The judge also expanded the three-year ban to prohibit Trudeau from disseminating or assisting to with infomercials (1"The Tan Sheet" March 28, 2005, p. 14)

You may also be interested in...



Supplement Marketer Trudeau Files False Advertising Suit Against FTC

Coral calcium marketer Kevin Trudeau is attempting to bar FTC from continuing to post a statement announcing a settlement of infomercial product claims litigation

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102524

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel